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Antibiotic prophylaxisa b s t r a c t
Although autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are fundamentally
different procedures, a tailored approach to bacterial bloodstream infection (BSI) according to the type of
HSCT has not yet been suggested. We evaluated the characteristics of BSI after HSCT, with a focus on
comparison of BSIs between recipients of autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT).
Among 134 patients (59 received allo-HSCT and 75 received auto-HSCT) who underwent HSCT, BSIs were
reported earlier in patients who underwent auto-HSCT, compared with those who underwent allo-HSCT
(mean 12.1  3.4 days versus 32.8  27.1 days, P ¼ .006). Among patients receiving allo-HSCT, post-
neutrophil-engraftment bacterial BSI showed an association with grade 2 acute graft-versus-host disease
(GVHD). In patients who underwent auto-HSCT, results of multivariate analysis showed that not receiving
prophylactic antibiotics (P ¼ .004) and having elevated serum C-reactive protein (P ¼ .034) were risk factors of
BSI. Elevated CRP (P ¼ .01) and acute GVHD  grade 2 (P ¼ .002) were independent risk factors in patients
who underwent allo-HSCT. Those differences originated mainly from the impact of acute GVHD-related
postengraftment BSIs of patients who underwent allo-HSCT. To establish the best defense strategy against
BSI, the distinctive natures of bacterial BSI after HSCT between auto-HSCT and allo-HSCT should be
considered.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bacterial bloodstream infection (BSI) is a common and
sometimes fatal event in patients who undergo hematopoi-
etic stem cell transplantation (HSCT). Although advances in
HSCT, such as the use of prophylactic antibiotics, reduced-
intensity conditioning (RIC), and improved supportive care,
have contributed to a substantial reduction of morbidity and
mortality, the incidence of bacterial BSI has been reported to
range from 20% to 43%, even after the year 2000 [1-4].
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factors, and mortality rates of BSI in HSCT recipients. Allo-
geneic HSCT (allo-HSCT), compared with autologous HSCT
(auto-HSCT) [4], status of underlying disease [4], and age>18
years [5] are frequently reported risk factors for bacterial BSI
among patients undergoing HSCT. In previous studies,
among recipients of allo-HSCT, HSCT from a matched unre-
lated donor (MUD) compared with HSCT from matched
sibling donor (MSD) [1,6], human leukocyte antigen (HLA)
matching [4,7], combined acute graft-versus-host disease
(GVHD) [5-7], and pretransplantation elevation of inﬂam-
matory markers, such as serum C-reactive protein (CRP) and
ferritin [8], have also been proposed as factors causing BSI.
Although auto-HSCT and allo-HSCT are fundamentally
different procedures, current guidelines [9-12] propose
uniform recommendations regarding bacterial infection,
including BSI, regardless of the type of HSCT. In a survey of
pharmacists from 31 transplantation centers (30 from the
United States and 1 from Mexico) taken during the 2003
Tandem BMT meeting in Keystone, Colorado, all centers re-
ported using a similar approach to bacterial prophylaxis for
auto-HSCT and allo-HSCT [13]. Few studies comparing the
nature of BSI according to the type of HSCT have been
reported.
In the current study, we evaluated pretransplantation
risk factors for BSI after HSCT, with a particular focus on
comparing BSIs between recipients of allo-HSCT and auto-
HSCT, to provide useful information for developing a tailored
strategy to overcoming BSI according to the type of HSCT.
MATERIALS AND METHODS
Patient Population
We analyzed a retrospective cohort of patients who underwent either
allo-HSCTor auto-HSCTat a single institution, Gachon University Gil Medical
Center, between November 2002 and June 2012. Patients were included if
they were age 18 years and had a complete set of clinical, laboratory, and
microbiologic data with well-preserved electronic medical records. Patients
who received a second HSCT were excluded from the current study. This
study was reviewed and approved by the Institutional Review Board of
Gachon University Gil Medical Center (approval number: GAIRB 2974-2012).
HSCT Procedures and Supportive Care for Prevention of Bacterial BSI
In most patients (121 of 134, 90.3%), a 7-French nontunneled subclavian
central venous catheter was inserted just before the start of conditioning,
and the other 13 patients underwent implantation of a 12-Frenchesized
tunneled Hickman catheter for HSCT. Transplantation procedures were
performed in single rooms containing a HEPA-ﬁltered laminar ﬂow hood. To
avoid exposing recipients to bacterial pathogens, health care workers in
contact with recipients were required to follow appropriate hand hygiene
practices. Although gowns or other protective clothing were not compul-
sory, visitors from outside the patients’ room were discouraged. A low-
bacteria diet was provided to the patients during the period of absolute
neutrophil count (ANC)<500/mL. In principle, antimicrobial prophylaxis was
decided according to the decision of attending physicians. However, the
prophylactic use of antibiotics was established as a general institutional
policy during the mid-2000s: until January 2006, only 1 of 22 patients
received prophylactic antibiotics, whereas 103 of 122 patients (84.4%) who
underwent HSCT thereafter received antibacterial prophylaxis. Since 2009,
every patient has received antibiotic prophylaxis. Patients receiving
prophylactic antibacterial antibiotics used ciproﬂoxacin 500 milligrams per
os twice daily from the start of conditioning until neutrophil engraftment.
Standard GVHD prophylaxis included either cyclosporine or tacrolimus in
combination with methotrexate.
Deﬁnitions and Report of Bacterial Bloodstream Infection
Blood cultures were obtained in response to fever or other suspicion of
systemic infection. The deﬁnition of BSI is as follows: (1) isolation of bacteria
not normally known to colonize the skin from at least 1 blood culture, or (2)
for bacteria that typically colonize the skin, such as coagulase-negative
Staphylococcus or viridians group of Streptococcus, the presence of either 2
consecutive positive blood cultures, 2 positive blood cultures within 3 days,
or 1 positive peripheral blood culture plus 1 positive blood culture fromthe central venous catheter site is required. A gram-negative isolate that
demonstrated resistance to at least 2 antibiotics used in empirical therapy
(third- and fourth-generation cephalosporins, carbapenems, or piperacillin-
tazobactam)wasdeﬁned asmulti-drug resistant (MDR). Day0was deﬁned as
the last date of stem cell infusion. Date of neutrophil engraftment was
deﬁned as the ﬁrst of at least 3 consecutive days of an ANC >500/mL. In the
current study, reports of bacterial BSIs fromday 0 todayþ100were analyzed.
Grading of acute GVHDwas performed according to established criteria [14].
Statistical Analysis
Potential risk factors of BSI were dichotomized and their relationships to
BSI were analyzed. Analyzed risk factors included type of HSCT (allogeneic
versus autologous), age (>40 versus 40 years, because the modiﬁed
European Group for Blood and Marrow Transplantation risk score [15]
classiﬁed age >40 years as a risk factor for inferior survival of patients
undergoing HSCTand we thought that BSI is one of themajor components of
overall poor treatment outcome of HSCT), gender, disease (acute myeloid
leukemia versus others), amount of infused CD34þ stem cell (5.0 versus
<5.0  106/kg, because 5.0  106/kg is usually regarded as the optimal
amount of peripheral blood stem cell collection [16]), HCT comorbidity
index score [17] (score 0 versus 1, considering the number of analyzed
patients in each group), and preceding use of antibiotics from conditioning
for prophylactic intent. The impact of blood levels of C-reactive protein (.5
mg/dL versus< .5 mg/dL) and albumin (3.5 mg/dL versus<3.5 mg/dL) was
evaluated according to the cut-off value of the institution. Ferritin values
within 10 days from the ﬁrst day of conditioning were also included in the
analysis (1000 ng/mL versus <1000 ng/mL according to the results of
a previous study [18]). Among patients who underwent allo-HSCT, modiﬁed
European Group for Blood and Marrow Transplantation score (0 to 2 versus
1, considering the number of analyzed patients in each group), concomi-
tant acute GVHD (grades 0 and 1 versus grade 2 [7]), type of donor, and
intensity of conditioning were also evaluated. To determine the association
between incidence of BSI and potential clinical and laboratory risk factors,
the Fisher exact test or the chi-square test were used as appropriate, and
multiple binary logistic regression tests were performed as univariate and
multivariate analysis. Independent variables with P < .1 were included for
multivariable analyses. All values were 2-sided and statistical signiﬁcance
was accepted at the level of P < .05.
RESULTS
Patient Characteristics
Out of 170 patients, 134 patients (78.8%) satisﬁed the
inclusion criteria (59 patients underwent allo-HSCT and 75
patients underwent auto-HSCT). Most patients who under-
went allo-HSCT (53 of 59 patients) and auto-HSCT (74 of 75
patients) acquired hematopoietic stem cells by peripheral
blood mobilization. Forty-four bacterial isolates from 36
patients (26.9%, 22 patients with allo-HSCT and 14 patients
for auto-HSCT) were reported. BSI occurred more frequently
in patients who underwent allo-HSCT (P¼ .019 by chi-square
test), compared with those who underwent auto-HSCT.
Detailed characteristics of the analyzed patients are shown
in Table 1.
BSIs of Allo-HSCT and Auto-HSCT
BSIs of auto-HSCT were reported earlier (mean [SD], 12.1
[3.4] days), compared with those of allo-HSCT (mean [SD],
32.8 [27.1] days), with statistical signiﬁcance (P ¼ .006 by
Mann-Whitney test). Contrary to patients who underwent
auto-HSCT who experienced no episodes of postneutrophil-
engraftment bacterial BSI, 8 of 22 patients (36.4%) who un-
derwent allo-HSCT experienced postneutrophil-engraftment
bacterial BSI, and 7 of the 8 patients had concomitant grade
2 acute GVHD.
MDR gram-negative bacterial BSI was more common in
patients who underwent allo-HSCT, compared with those
who underwent auto-HSCT. BSIs after allo-HSCT were more
fatal: 7 of 21 patients who underwent allo-HSCT (33.3%) died
of BSI, whereas only 1 of 14 patients who underwent auto-
HSCT died of BSI. Mortality due to catheter-related BSI was
higher among patients who underwent allo-HSCT, compared
with those who underwent auto-HSCT (Table 2).
Table 1
Patient Characteristics
Potential Risk Factor Overall (N ¼ 134) Allo-HSCT (n ¼ 59) Auto-HSCT (n ¼ 75)
Age, yr
Median (range) 45 (18-68) 35 51 (22-68)
40 49 (36.5%) 35 (59.3%) 14 (18.7%)
>40 85 24 61
Gender
Male 77 (57.5%) 29 (49.2%) 48 (64.0%)
Female 57 30 27
Disease
Acute myeloid leukemia 41 (30.6%) 31 (52.5%) 10 (13.3%)
Others 93 (69.4%) 28 (47.5%) 65 (86.7%)
Acute lymphoblastic leukemia 5 5 0
Biphynotypic acute leukemia 6 6 0
Myelodysplastic syndrome 3 3 0
Severe aplastic anemia 5 5 0
Chronic myelogenous leukemia 6 6 0
Lymphoma 30 1 29
Multiple myeloma 38 2 36
Time of transplantation
180 d 85 (63.4%) 30 (50.8%) 55 (73.3%)
>180 d 49 29 20
CD34þ cell
Median (range) 4.17 (1.0-20.0) 3.80 (1.0-17.0) 5.48 (1.2-20.0)
5.0  106/kg 44 (32.8%) 17 (28.8%) 27 (36.0%)
<5.0  106/kg 81 (60.4%) 41 (69.5%) 40 (53.3%)
No record 9 1 8
HCT-CI
Score 0 92 (68.7%) 48 (81.4%) 44 (58.7%)
Score 1 42 11 31
Prophylactic antibiotics
Yes 104 (77.6%) 43 (72.9%) 61 (81.3%)
No 30 16 14
Elevated C-reactive protein
Yes 65 (48.5%) 35 (59.3%) 30 (40.0%)
No 69 24 45
Serum albumin
3.5 mg/dL 99 (73.9%) 39 (66.1%) 60 (80.0%)
<3.5 mg/dL 35 20 15
Serum ferritin
1000 ng/mL 41 (30.6%) 29 (49.2%) 12 (16.0%)
<1000 ng/mL 75 (56.0%) 26 (44.1%) 49 (65.3%)
Not checked 18 4 14
mEBMT score after allograft
Score 0 to 2 - 31 (52.5%) -
Score 3 - 28 -
Acute GVHD
Grade 0 to 1 - 39 (66.1%) -
Grade 2 - 13 (22.0%) -
Not evaluable (early death) 7
Source of allograft
Matched sibling - 33 (55.9%) -
Others - 26 (44.1%) -
Matched unrelated 24
1-locus mismatched unrelated 1
Umbilical cord blood 1
Conditioning of allograft
Myeloablative - 52 (88.1%) -
Nonmyeloablative - 7 -
Status before allograft
In CR - 52 (88.1%) -
Not in CR - 7 -
Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; d, days; HCT-CI,
hematopoietic cell transplantation-comorbidity index; mEBMT, modiﬁed European Group for Blood and Marrow Transplantation; CR, complete remission.
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Typeof centralvenouscatheterdidnothavean inﬂuenceon
the incidence of catheter-related BSI: 2 of 13 patients (15.3%)
with a Hickman catheter and 9 of 121 patients (7.4%) with
a nontunneled central venous catheter experienced catheter
related BSI (P ¼ .214). Elevated CRP (P < .001) and no prophy-
lactic antibiotics (P < .021) showed independent associations
with higher incidence of BSI in the entire patient population.In multivariate analysis, among 59 patients who under-
went allo-HSCT, elevated CRP (P ¼ .01) and acute GVHD 
grade 2 (P ¼ .002) showed associations with BSI. For 75
patients who underwent auto-HSCT, elevated CRP (P ¼ .034)
and no prophylactic antibiotic use (P ¼ .004) were found to
be independent risk factors of BSI. In multivariate analysis of
the entire patient population, CRP elevation and no antibiotic
prophylaxis maintained signiﬁcant risk (Table 3).
Table 2
Etiologic Agents of Bacterial Bloodstream Infection
Allo-HSCT 28 Bacterial Isolates from 22 Patients Auto-HSCT 16 Bacterial Isolates from 14 Patients
Gram positive Overall reported BSIs: 10 isolates Overall reported BSIs: 5 isolates
Methicillin-resistant (MR) CNS: 5 MRCNS: 2
Methicillin-susceptible (MS) SA: 1 MSSA: 1
MRSA: 1 MRSA: 1
Vancomycin-susceptible Enterococcus: 1 a-hemolytic Streptococcus: 1
Vancomycin-resistant Enterococcus: 2
Deﬁned as catheter-related BSI: 7 isolates Deﬁned as catheter-related BSI: 4 isolates
Fatal BSI: 4 isolates Fatal BSI: none
1 patient died of MCRNS
1 patient died of VRE
1 patient died of MRSA
1 patient died with VRE (died of disease Progression)
Gram negative Overall reported BSIs: 18 isolates Overall reported BSIs: 11 isolates
Klebsiella pneumoniae: 3 K. pneumoniae: 6
Escherichia coli: 5 E. coli: 3
Acinetobacter baumanii: 3 Citrobacter braakii: 1
Enterobacter cloacae: 2 Agrobacterium radiobacter: 1
Sternotrophomonas maltophilia: 2
Pseudomonas aerusinosa: 1
Undeﬁned gram (-) rods: 2
Deﬁned as MDR gram (-) rods: 8 isolates Deﬁned as MDR-gram (-) rods: 1 isolate
Fatal BSI: 3 isolates Fatal BSI: 1 isolate
2 patients died of MDR A. baumanii 1 patient died of K. pneumoniae
1 patient died with MDR undeﬁned g(-) rod (died
of massive intestinal bleeding)
Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; BSI, bloodstream
infection; CNS, coagulase-negative staphylococci; SA, Staphylococcus aureus; MDR, multi-drug resistant.
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In the current study, different characteristics of bacterial
BSI were observed between patients who underwent allo-
HSCT and those who underwent auto-HSCT, although
patients in both groups received identical supportive care to
prevent bacterial infection during the HSCT procedure.
A beneﬁcial role of prophylactic antibiotics in patients
with auto-HSCT was demonstrated in our study as well as
in a previous meta-analysis [19]. Because the majority of
BSI events occurred during the preneutrophil-engraftment
period, with relatively less incidence of BSI by MDRTable 3
Univariate and Multivariate Analysis for Risk Factors of Bacterial Bloodstream Infec
Potential Risk Factor Overall (N ¼ 134) Allo-H
OR 95% CI P OR
Univariate analysis
Allogeneic transplantation 2.59 1.18-5.68 .017
Age >40 yr .64 .29-1.38 .253 1.37
Male gender .66 .31-1.43 .291 .59
Acute myeloid leukemia 2.34 1.05-5.19 .037 1.14
CD34þ cell <5.0  106/kg 2.36 .93-6.01 .072 1.06
HCT-CI score 1 .95 .42-2.18 .905 2.40
Without antibiotics 5.85 2.43-14.06 <.001 1.45
Elevated CRP 7.14 2.84-17.94 <.001 5.30
Serum albumin <3.5 mg/dL 2.33 1.02-5.33 .044 3.11
Serum ferritin >1000 ng/mL 2.02 .84-4.87 .116 1.92
Modiﬁed EBMT score 3 Not analyzed 1.18
Acute GVHD grade 2 Not analyzed 15.95
Not matched sibling donor Not analyzed .91
Myeloablative conditioning Not analyzed 1.56
Transplantation without CR Not analyzed .69
Multiple myeloma Not analyzed Not an
Multivariate analysis
Without antibiotics 3.32 1.20-9.21 .021 -
Elevated CRP 7.38 2.51-21.67 <.001 8.97
Acute GVHD grade 2 - 20.96
OR indicates odds ratio; CI, conﬁdence interval; CRP, C-reactive protein; HCT-CI, he
for Blood and Marrow Transplantation; GVHD, graft-versus-host disease; CR, compathogen, it can be assumed that early introduction of broad-
spectrum antibiotics as a prophylaxis for bacterial BSI could
lead to reduced incidence of bacterial BSI in patients
receiving auto-HSCT: it appears to be an one-shot game
decided by a single round. However, to provide conﬁrmation,
further prospective studies are needed.
Among patients who underwent allo-HSCT, the inci-
dence of bacterial BSI showed a signiﬁcant increase
according to the occurrence of grade 2 acute GVHD:
among 13 patients with grade 2 acute GVHD, 11 patients
had a bacterial BSI and 10 of them experienced BSI aftertion
SCT (n ¼ 59) Auto-HSCT (n ¼ 75)
95% CI P OR 95% CI P
.47-3.99 .565 .49 .13-1.88 .298
.20-1.71 .330 1.02 .30-3.41 .980
.40-3.28 .812 3.67 .87-15.37 .076
.33-3.44 .926 8.67 1.04-72.32 .046
.64-9.07 .197 .75 .22-2.50 .637
.45-4.68 .532 35.63 7.64-166.21 <.001
1.50-18.70 .010 8.11 2.03-32.44 .003
1.01-9.57 .048 1.11 .27-4.63 .882
.61-5.98 .263 .55 .61-4.91 .589
.41-3.39 .763 Not analyzed
3.00-84.67 .001 Not analyzed
.32-2.64 .869 Not analyzed
.28-8.84 .614 Not analyzed
.16-2.99 .624 Not analyzed
alyzed 1.86 .56-6.19 .312
19.77 2.57-152.29 .004
1.70-47.42 .010 12.74 1.22-133.48 .034
2.98-147.35 .002 -
matopoietic cell transplantation-comorbidity index; EBMT, European Group
plete remission.
J. Hong et al. / Biol Blood Marrow Transplant 19 (2013) 988e999998initiating corticosteroids with or without immunosup-
pressant for treatment of acute GVHD during the
postneutrophil-engraftment period. In addition, 8 of the 10
patients, patients had a report indicating growth of resistant
bacteria; MDR-gram negative rods (n ¼ 4), vancomycin-
resistant Enterococcus (n ¼ 2), and methicillin-resistant
coagulase-negative staphylococci (n ¼ 2). Strong associa-
tion of acute GVHD with an increase of bacterial BSI has
been reported in several previous studies [5-7]. Poutsiaka
et al. [7] reported an association of BSI and acute GVHD after
HSCT. In their study, no relationship was observed between
the occurrence of BSI and acute GVHD grade 1, and only
acute GVHD grades 2 showed an association with inci-
dence of BSI. They reported that median time to develop-
ment of acute GVHD grades 2 (49 of 211 patients, 23.2%)
was 24 days (interquartile range, 16 to 36 days). Regarding
these results, we can assume that development of moderate
to severe acute GVHD and subsequent administration of
systemic corticosteroids with or without immunosuppres-
sant may contribute to higher and later occurrence of
bacterial BSI in patients receiving allo-HSCT, compared with
those receiving auto-HSCT. Although we did not evaluate
the direct correlation between use of systemic steroids and
incidence of BSI, it can be easily postulated because all 13
patients with acute GVHD grade 2 received systemic
steroids with a dose of 1 mg/kg of prednisolone or
equivalent, whereas only 2 of 46 patients with no or grade 1
acute GVHD received systemic corticosteroids. Because none
of the 13 patients received prophylactic antibiotics in
response to acute GVHD grade 2 and its resultant systemic
corticosteroid use, the effect of prophylactic antibiotics for
prevention of bacterial infection during systemic treatment
of moderate to severe acute GVHD could not be evaluated.
Antibiotic prophylaxis failed to result in a decrease of
bacterial BSI in patients who underwent allo-HSCT. Recent
studies have also reported a limited role of the current
antibiotic prophylaxis in the setting of allo-HSCT: a Canadian
prospective study was conducted for comparison of 2
consecutive cohorts (empiric antibacterial strategy [n ¼ 127]
versus prophylactic strategy [n ¼ 111]) of patients receiving
outpatient-based HSCT [20]. Prophylactic use of antibiotics
contributed to a reduction of bacterial BSI in patients who
underwent auto-HSCT (P ¼ .001), but not in those who
underwent allo-HSCT (P¼ .19). In a retrospective study of 246
patients who underwent allo-HSCT, a new quinolone-based
prophylactic antibiotic regimen showed no superiority to
the old regimen (trimethoprime sulfamethoxazole, vanco-
mycin, and nystatin, all per os) in terms of the occurrence of
BSI and 6-month mortality [21]. However, with still insufﬁ-
cient evidence, it is dangerous to conclude that administra-
tion of prophylactic antibiotics is unnecessary in allo-HSCT
recipients. Rather, it is more reasonable to explain that the
beneﬁcial effect of prophylactic antibiotics was counter-
balanced by BSIs of later onset and more resistant pathogens
caused by post-allo-HSCT conditions, such as prolonged use
of immunosuppressant because of acute GVHD, etc.
Greater frequency of MDR bacterial isolates among
patients with allo-HSCT can be explained by the baseline
patient characteristics. Most patients who underwent allo-
HSCT had acute leukemia, myelodysplastic syndrome, or
aplastic anemia, and they experienced more prolonged
periods of neutropenia in general, compared with patients
with lymphoma or multiple myeloma; therefore, they
received more repeated and heavy treatment with broad-
spectrum antibiotics. A signiﬁcant increase in cases ofMDR bacterial infection has been reported in patients with
allo-HSCT [2-3,22], and they are one of the critical factors
causing mortality [3,22]; therefore, antibiotic resistance is
a major concern of allo-HSCT. Oliveira et al. [3] prospectively
collected data from 13 Brazilian HSCT centers to characterize
the epidemiology of BSI and to identify factors associated
with infection due to MDR gram-negative isolates. They
reported an association with treatment with third-
generation cephalosporin and being a patient at one of
the hospitals with infection due to MDR gram-negative
isolates. Results of a retrospective cohort study conducted
by the Mayo Clinic revealed that prophylactic levoﬂoxacin
with penicillin (or doxycycline for penicillin-allergic
patients) may contribute to the emergence of resistant
gram-negative infections in allo-HSCT recipients over time
[23]. Considering these previous studies and the result of
the current study showing that the majority of BSIs
combined with acute GVHD grade 2 were caused by
resistant pathogens, routine prophylactic antibiotic use in
response to acute GVHD grade 2 may not be an effective
strategy. Rather, close observation of patients with repeti-
tive and thorough history taking and physical examination,
regular checks of chest X-ray and blood inﬂammatory
markers, and consultation with infectious disease specialists
could be a better approach. Empiric antibiotics should be
chosen by infectious disease specialists considering not only
the patient’s previous history of antibiotic use, but also the
particularity of the institution.
Although serum CRP is a nonspeciﬁc inﬂammatory
marker, elevated CRP (.5 mg/dL) before transplantation
remained an independent risk factor in multivariate analysis.
This result is in line with ﬁndings of a previous study re-
ported by Kanda et al. [8], although a higher level of serum
ferritin is not. Because .5 mg/dL was the upper limit of the
normal range of CRP in our institution, we used a different
cut-off value of serum CRP (.5 mg/dL) compared with that
reported in the study by Kanda et al. (.3 mg/dL). Whether .3
mg/dL or .5 mg/dL was used as a cut off, elevation of baseline
CRP was proven to be an independent risk factor of bacterial
BSI by at least 2 retrospective studies. Considering the re-
sults, a stronger recommendation of prophylactic antibiotic
use for patients with elevated CRP could be cautiously
considered, at least in the case of auto-HSCT.
Posttransplantation CRP elevation is also known to be
related to transplantation-related complications in patients
receiving allo-HSCT [24-25]. To determine if serum CRP
before HSCT is a predictive factor of bacterial BSI, a prospec-
tive study in patients with HSCT is warranted.
Contrary to a previous study conducted in the1990s that
reported HSCT with a MUD donor, compared with HSCT with
an MSD donor, was as a risk factor for bacterial BSI [6], in the
current study, the source of the allograft had no impact on
the risk of bacterial BSI. However, improvement of acute
GVHD prophylaxis might reduce the incidence of acute
GVHD and resultant bacterial infection. Because of a small
sample size and the retrospective nature of the current study,
we cannot make a conclusive statement that MUD is
comparable to MSD in terms of bacterial BSI. We believe that
this should be validated in future studies. As most patients
who underwent allo-HSCT had either MSD (n ¼ 33) or MUD
(n ¼ 24) as a source of allograft, we could not evaluate the
risk of BSIs in patients with alternative sources of allografts,
such as those from HLA-mismatched donors, haplo-identical
donors, and umbilical cord blood transplantation. This
should also be evaluated in the future analysis.
J. Hong et al. / Biol Blood Marrow Transplant 19 (2013) 988e999 999Limitations of the current study include a relatively small
number of patients and retrospective analysis. However, the
results of our study demonstrate differences between
bacterial BSIs after auto-HSCT and allo-HSCT clearly enough
to provide useful information for developing a future
strategy to overcoming BSI according to the type of HSCT.
In conclusion, except for elevation of pretransplantation
serum CRP, allo-HSCT and auto-HSCT have different risk
factors, and BSI after auto-HSCT occurred earlier and showed
better clinical outcomes compared with BSI after allo-HSCT.
To establish the best defense strategy against BSI, the
distinctive natures of bacterial BSI after allo-HSCT and auto-
HSCT should be considered.
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